A gene-expression signature as a predictor of survival in breast cancer.
(2010). A: Identification of subtypes in human epidermal growth factor receptor 2–positive breast cancer reveals a gene signature prognostic of outcome.
(2005). An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA
(2007). An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol
(2007). Bhanot G: High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res
(2003). Botstein D: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA
(2006). BørresenDale AL: Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms.
(2008). C: A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer. Breast Cancer Res
(2006). Cell-type specific gene expression profiles of leukocytes in human peripheral blood.
(1998). Cluster analysis and display of genome-wide expression patterns.
(2009). de Vijver MJ: Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas.
(2005). Etten RA: Tyrosine kinases as targets for cancer therapy.
(2011). F: A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res Treat
(2008). F: Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. Cancer Res
(2005). Foekens JA: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet
(2011). Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat
(2006). Gene expression profiling and clinical outcome in breast cancer. Omics
(2006). Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.
(2009). Gene expression profiling of breast cancer.
(2006). Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene
(2005). Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res
(2008). How basal are triple-negative breast cancers?
(2009). Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clin Cancer Res
(2007). Iggo RD: Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol
(2010). Immune regulation of cancer.
Ingenuity Pathways Analysis v8.0-2602
(2006). L: Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
(2006). LD: Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res
(2008). Lopez-Guillermo A, et al: Stromal gene signatures in large-B-cell lymphomas.
(2002). López-Guillermo A, et al: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
(2005). Mesirov JP: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA
(2000). Molecular portraits of human breast tumours. Nature
(2004). MR: A census of human cancer genes. Nat Rev Cancer
(1993). P: FGFRI and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers. Genes Chromosomes Cancer
(2009). Park KH: Immunomodulation of Breast Cancer via Tumor Antigen Specific Th1. Cancer Res Treat
(2006). Perou CM: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics
(2002). SH: Gene expression profiling predicts clinical outcome of breast cancer.
(2008). Sotiriou C: Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res
(2003). Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics
(2005). Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics: Reporting recommendations for tumor marker prognostic studies.
(2002). Sudarsanam S: The protein kinase complement of the human genome. Science
(2009). Sültmann H: Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer. Breast Cancer Res Treat
(2009). T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res
(2007). Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat rev cancer
(2007). TRANSBIG Consortium: Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res
(2010). Triche TJ: Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children’s oncology group.
(2009). Use of tumour-responsive T cells as cancer treatment. Lancet